Cigna Group
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
CI$295.60+0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
FS-7
SCHEDULE II
VALUATION AND QUALIFYING ACCOUNTS AND RESERVES
| (In millions) | Balance at Beginning of Year | Charged (Credited) to Costs and Expenses | Charged (Credited) to Other Accounts | Other Deductions | Balance at End of Year |
|---|---|---|---|---|---|
| Description | |||||
| Investment asset valuation reserves | |||||
| Available-for-sale debt securities | $111 | $58 | $— | $(32) | $137 |
| Commercial mortgage loans | $30 | $6 | $— | $— | $36 |
| Accounts receivable, net | $186 | $245 | $2 | $(175) | $258 |
| Deferred tax asset valuation allowance | $2,332 | $317 | $(275) | $— | $2,374 |
| Reinsurance recoverables | $30 | $(7) | $— | $— | $23 |
| Investment asset valuation reserves | |||||
| Available-for-sale debt securities | $33 | $87 | $— | $(9) | $111 |
| Commercial mortgage loans | $31 | $(1) | $— | $— | $30 |
| Accounts receivable, net | $163 | $176 | $(1) | $(152) | $186 |
| Deferred tax asset valuation allowance | $1,498 | $866 | $(32) | $— | $2,332 |
| Reinsurance recoverables | $35 | $(5) | $— | $— | $30 |
| Investment asset valuation reserves | |||||
| Available-for-sale debt securities | $44 | $11 | $— | $(22) | $33 |
| Commercial mortgage loans | $21 | $10 | $— | $— | $31 |
| Accounts receivable, net | $160 | $90 | $1 | $(88) | $163 |
| Deferred tax asset valuation allowance | $208 | $1,286 | $4 | $— | $1,498 |
| Reinsurance recoverables | $35 | $— | $— | $— | $35 |
FS-7
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.